Contiguous Stage II Marginal Zone Lymphoma Completed Phase 2 Trials for Tacrolimus (DB00864)

IndicationStatusPhase
DBCOND0029471 (Contiguous Stage II Marginal Zone Lymphoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00089011Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic CancerTreatment
NCT00489203Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerSupportive Care
NCT01789255Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological MalignanciesSupportive Care